Login / Signup

Immune-related adverse events associated with mogamulizumab: a comprehensive review of the literature.

Genevieve S SilvaEllen J KimStefan K BartaJina Chung
Published in: Expert review of anticancer therapy (2024)
Mogamulizumab's ability to augment the host immune response through Treg depletion adds to its efficacy but has wide-ranging implications for autoimmunity across multiple organ systems, similar to immune checkpoint inhibitor therapy. Occurrence of irAEs may be associated with improved overall clinical response, although long-term follow-up studies are needed.
Keyphrases
  • immune response
  • risk assessment
  • dendritic cells
  • toll like receptor
  • stem cells
  • bone marrow
  • mesenchymal stem cells
  • celiac disease